New Drug Could Reduce Phlebotomies for PV Patients
A Phase 3 study shows that rusfertide may help adults with polycythemia vera lower their frequency of blood-letting procedures.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Do you believe medical treatments should prioritize patient comfort as much as clinical test results?
A Phase 3 study shows that the experimental drug rusfertide helps patients with polycythemia vera reduce their need for therapeutic phlebotomy. The treatment also improved patient-reported fatigue levels, offering a potential new option for those struggling to keep their hematocrit levels under control.
Why it matters
Managing polycythemia vera often requires frequent phlebotomies to maintain safe hematocrit levels, which can be burdensome for patients. This new, potential treatment option could provide a way to reduce that frequency and better control the blood condition.
The Phase 3 VERIFY trial evaluated 293 patients with polycythemia vera, finding that 77% of those on rusfertide reached a clinical response compared to 33% in the placebo group. The study results, published October 13, 2026, also noted that 7% of treated patients experienced grade 3 or worse adverse events.
The players
JCO
A peer-reviewed medical journal that publishes original research on oncology and related blood disorders.
The details
Rusfertide acts as a peptide mimetic of hepcidin, a hormone that regulates iron metabolism and blocks the excessive production of red blood cells known as erythrocytosis. By mimicking this hormone, the drug helps prevent the hematocrit from exceeding the target threshold of 45%. Clinical trial participants were randomized to receive the medication or a placebo, with the most commonly reported side effects including fatigue, anemia, and injection site reactions.
Timeline
Baseline measurements for phlebotomy and hematocrit were recorded 32 weeks prior to treatment.
Part 1a of the clinical trial occurred over a 32-week period.
The VERIFY study results were published in JCO on October 13, 2026.
Health Landscape
Standard care for polycythemia vera currently relies on frequent therapeutic phlebotomy to manage red blood cell volume. The VERIFY trial indicates a shift toward potentially integrating peptide-based pharmacological interventions into the traditional management arc.
If you or a loved one are managing polycythemia vera, this research highlights a new mechanism for stabilizing hematocrit levels that may reduce the need for repeat phlebotomies. Discuss these findings with your hematologist to understand how future treatment options might align with your specific care plan.
The takeaway
Rusfertide shows promise in reducing phlebotomy dependency for polycythemia vera patients while maintaining hematocrit targets. Patients should continue to monitor their blood work closely and work with their care team to maintain hematocrit levels below 45%.
Further reading
Learn more about new therapeutic approaches in the Cancer section.
More information
View the full trial data on the ClinicalTrials.gov study registration page.
Source note: This article includes information reported by Oncology Nurse Advisor.
Live Poll
Do you believe medical treatments should prioritize patient comfort as much as clinical test results?
